Literature DB >> 34240212

Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder.

Christophe Moderie1,2, Philippe Boudreau1, Ari Shechter3, Paul Lespérance4, Diane B Boivin1,2.   

Abstract

We previously found normal polysomnographic (PSG) sleep efficiency, increased slow-wave sleep (SWS), and a blunted melatonin secretion in women with premenstrual dysphoric disorder (PMDD) compared to controls. Here, we investigated the effects of exogenous melatonin in five patients previously studied. They took 2 mg of slow-release melatonin 1 h before bedtime during their luteal phase (LP) for three menstrual cycles. At baseline, patients spent every third night throughout one menstrual cycle sleeping in the laboratory. Measures included morning urinary 6-sulfatoxymelatonin (aMt6), PSG sleep, nocturnal core body temperature (CBT), visual analog scale for mood (VAS-Mood), Prospective Record of the Impact and Severity of Menstrual Symptoms (PRISM), and ovarian plasma hormones. Participants also underwent two 24-hour intensive physiological monitoring (during the follicular phase and LP) in time-isolation/constant conditions to determine 24-hour plasma melatonin and CBT rhythms. The same measures were repeated during their third menstrual cycle of melatonin administration. In the intervention condition compared to baseline, we found increased urinary aMt6 (p < 0.001), reduced objective sleep onset latency (p = 0.01), reduced SWS (p < 0.001), and increased Stage 2 sleep (p < 0.001). Increased urinary aMt6 was correlated with reduced SWS (r = -0.51, p < 0.001). Circadian parameters derived from 24-hour plasma melatonin and CBT did not differ between conditions, except for an increased melatonin mesor in the intervention condition (p = 0.01). Ovarian hormones were comparable between the conditions (p ≥ 0.28). Symptoms improved in the intervention condition, as measured by the VAS-Mood (p = 0.02) and the PRISM (p < 0.001). These findings support a role for disturbed melatonergic system in PMDD that can be partially corrected by exogenous melatonin. © Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  body temperature; circadian rhythm; melatonin; menstrual cycle; mood; premenstrual dysphoric disorder; sleep

Mesh:

Substances:

Year:  2021        PMID: 34240212      PMCID: PMC8664575          DOI: 10.1093/sleep/zsab171

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   6.313


  90 in total

1.  Oral contraceptives alter sleep and raise body temperature in young women.

Authors:  F C Baker; D Mitchell; H S Driver
Journal:  Pflugers Arch       Date:  2001-08       Impact factor: 3.657

2.  Action of progesterone on preoptic thermosensitive neurones.

Authors:  T Nakayama; M Suzuki; N Ishizuka
Journal:  Nature       Date:  1975-11-06       Impact factor: 49.962

3.  Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.

Authors:  Birgitta Segebladh; Anna Borgström; Sigrid Nyberg; Marie Bixo; Inger Sundström-Poromaa
Journal:  Am J Obstet Gynecol       Date:  2009-04-26       Impact factor: 8.661

4.  Effects of pinealectomy on regional brain serotonin metabolism.

Authors:  M Aldegunde; I Miguez; J Veira
Journal:  Int J Neurosci       Date:  1985-04       Impact factor: 2.292

5.  The progesterone metabolite allopregnanolone potentiates GABA(A) receptor-mediated inhibition of 5-HT neuronal activity.

Authors:  Vikas Kaura; Colin D Ingram; Sarah E Gartside; Allan H Young; Sarah J Judge
Journal:  Eur Neuropsychopharmacol       Date:  2006-03-06       Impact factor: 4.600

6.  Compliance to antidepressant drug therapy for treatment of premenstrual syndrome.

Authors:  I Sundström-Poromaa; M Bixo; I Björn; O Nordh
Journal:  J Psychosom Obstet Gynaecol       Date:  2000-12       Impact factor: 2.949

7.  ISPMD consensus on the management of premenstrual disorders.

Authors:  Tracy Nevatte; Patrick Michael Shaughn O'Brien; Torbjorn Bäckström; Candace Brown; Lorraine Dennerstein; Jean Endicott; C Neill Epperson; Elias Eriksson; Ellen W Freeman; Uriel Halbreich; Khalid Ismail; Nicholas Panay; Teri Pearlstein; Andrea Rapkin; Robert Reid; David Rubinow; Peter Schmidt; Meir Steiner; John Studd; Inger Sundström-Poromaa; Kimberly Yonkers
Journal:  Arch Womens Ment Health       Date:  2013-04-27       Impact factor: 3.633

Review 8.  Homeostatic versus circadian effects of melatonin on core body temperature in humans.

Authors:  A Cagnacci; K Kräuchi; A Wirz-Justice; A Volpe
Journal:  J Biol Rhythms       Date:  1997-12       Impact factor: 3.182

9.  The subjective meaning of sleep quality: a comparison of individuals with and without insomnia.

Authors:  Allison G Harvey; Kathleen Stinson; Katriina L Whitaker; Damian Moskovitz; Harvinder Virk
Journal:  Sleep       Date:  2008-03       Impact factor: 5.849

10.  Meta-analysis: melatonin for the treatment of primary sleep disorders.

Authors:  Eduardo Ferracioli-Oda; Ahmad Qawasmi; Michael H Bloch
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.